Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer

This publication has 37 references indexed in Scilit:

• Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion
  Journal of Thoracic Oncology, 2023
• Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
  Cancer Cell, 2022
• 35P Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)
  Annals of Oncology, 2022
• Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
  JAMA Oncology, 2021
• A newly developed capture-based sequencing panel for genomic assay of lung cancer
  Genes & Genomics, 2020
• Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
  Journal of Cancer Research and Clinical Oncology, 2020
• MACC1—the first decade of a key metastasis molecule from gene discovery to clinical translation
  Cancer and Metastasis Reviews, 2018
• Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC
  Lung Cancer, 2017
• Translesion Polymerases Drive Microhomology-Mediated Break-Induced Replication Leading to Complex Chromosomal Rearrangements
  Molecular Cell, 2015
• EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
  The Lancet Oncology, 2012